Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

European Journal of Cancer

Volumn 51, Issue 14, 2015, Pages 1978-1988

  Matsuo, Koji ^a,b   Hasegawa, Kosei ^c   Yoshino, Kiyoshi ^d   Murakami, Ryusuke ^e   Hisamatsu, Takeshi ^d,f   Stone, Rebecca L ^g   Previs, Rebecca A ^f   Hansen, Jean M ^f   Ikeda, Yuji ^c,h   Miyara, Akiko ^c   Hiramatsu, Kosuke ^d   Enomoto, Takayuki ⁱ   Fujiwara, Keiichi ^c   Matsumura, Noriomi ^e   Konishi, Ikuo ^e   Roman, Lynda D ^a,b   Gabra, Hani ^j   Fotopoulou, Christina ^j   Sood, Anil K ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f UNIVERSITY OF TEXAS   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Clear cell carcinoma; IL 6; Ovarian cancer; Survival outcome; Venous thromboembolism

Indexed keywords

CA 125 ANTIGEN; INTERLEUKIN 6; IL6 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SPLENECTOMY; THROMBOCYTOSIS; TUMOR VOLUME; VENOUS THROMBOEMBOLISM; AGED; BLOOD; CANCER STAGING; CARCINOMA; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; INCIDENCE; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TUMOR RECURRENCE; UNITED STATES; UPREGULATION;

ADULT; AGED; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; INTERLEUKIN-6; JAPAN; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UP-REGULATION; VENOUS THROMBOEMBOLISM;

EID: 84939576164     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.07.012     Document Type: Article

References (37)

1. P.L. Sung, Y.H. Chang, K.C. Chao, and C.M. Chuang Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review Gynecol Oncol 133 2014 147 154
2. M.S. Anglesio, M.S. Carey, M. Kobel, H. Mackay, and D.G. Huntsman Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010 Gynecol Oncol 121 2011 407 415
3. S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, J.D. Brenton, and et al. Rethinking ovarian cancer: recommendations for improving outcomes Nat Rev Cancer 11 2011 719 725
4. M.G. del Carmen, M. Birrer, and J.O. Schorge Clear cell carcinoma of the ovary: a review of the literature Gynecol Oncol 126 2012 481 490
5. E.I. Braicu, J. Sehouli, R. Richter, K. Pietzner, C. Denkert, and C. Fotopoulou Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers Br J Cancer 105 2011 1818 1824
6. J.H. Farley, W.E. Brady, M.J. Birrer, D.M. Gershenson, and G.F. Fleming An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience J Clin Oncol 31 suppl 2013 abstr 5534
7. C.C. Gunderson, E.D. Thomas, K.N. Slaughter, R. Farrell, K. Ding, R.E. Farris, and et al. The survival detriment of venous thromboembolism with epithelial ovarian cancer Gynecol Oncol 134 2014 73 77
8. C. Fotopoulou, A. duBois, A.N. Karavas, R. Trappe, B. Aminossadati, B. Schmalfeldt, and et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group J Clin Oncol 26 2008 2683 2689
9. E.S. Diaz, A.E. Walts, B.Y. Karlan, and C.S. Walsh Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival Gynecol Oncol 131 2013 541 545
10. Y. Matsuura, G. Robertson, D.E. Marsden, S.N. Kim, V. Gebski, and N.F. Hacker Thromboembolic complications in patients with clear cell carcinoma of the ovary Gynecol Oncol 104 2007 406 410
11. L.R. Duska, L. Garrett, M. Henretta, J.S. Ferriss, L. Lee, and N. Horowitz When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes Gynecol Oncol 116 2009 374 377
12. M.S. Anglesio, J. George, H. Kulbe, M. Friedlander, D. Rischin, C. Lemech, and et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer Clin Cancer Res 17 2011 2538 2548
13. R.L. Stone, A.M. Nick, I.A. McNeish, F. Balkwill, H.D. Han, J. Bottsford-Miller, and et al. Paraneoplastic thrombocytosis in ovarian cancer N Engl J Med 366 2012 610 618
14. A.N. Davis, V. Afshar-Kharghan, and A.K. Sood Platelet effects on ovarian cancer Semin Oncol 41 2014 378 384
15. R. Kerr, D. Stirling, and C.A. Ludlam Interleukin 6 and haemostasis Br J Haematol 115 2001 3 12
16. O. Fadare Clear cell carcinomas of the gynecologic tract and thromboembolic events: what do we know so far? Womens Health (Lond Engl) 10 2014 479 481
17. STROBE guideline at http://www.strobe-statement.org/ [accessed April 2015].
18. K. Matsuo, A.A. Yessaian, Y.G. Lin, H.Q. Pham, L.I. Muderspach, H.A. Liebman, and et al. Predictive model of venous thromboembolism in endometrial cancer Gynecol Oncol 128 2012 544 551
19. J. Prat Staging classification for cancer of the ovary, fallopian tube, and peritoneum Int J Gynaecol Obstet 124 2013 1 5
20. T.R. Rosean, V.S. Tompkins, A.K. Olivier, R. Sompallae, L.A. Norian, H.C. Morse 3rd, and et al. The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice Leukemia 29 2015 233 237
21. L. Zhang, J. Yang, J. Qian, H. Li, J.E. Romaguera, L.W. Kwak, and et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells Blood 120 2012 3783 3792
22. N. Yanaihara, M.S. Anglesio, K. Ochiai, Y. Hirata, M. Saito, C. Nagata, and et al. Cytokine gene expression signature in ovarian clear cell carcinoma Int J Oncol 41 2012 1094 1100
23. M.B. Nilsson, R.R. Langley, and I.J. Fidler Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine Cancer Res 65 2005 10794 10800
24. J.I. Coward, and H. Kulbe The role of interleukin-6 in gynaecological malignancies Cytokine Growth Factor Rev 23 2011 333 342
25. S. Yamamoto, I. Konishi, M. Mandai, H. Kuroda, T. Komatsu, K. Nanbu, and et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels Br J Cancer 76 1997 1221 1227
26. E.M. Reitter, C. Ay, A. Kaider, R. Pirker, C. Zielinski, G. Zlabinger, and et al. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients Clin Exp Immunol 177 2014 253 260
27. G.C. Connolly, R.P. Phipps, and C.W. Francis Platelets and cancer-associated thrombosis Semin Oncol 41 2014 302 310
28. R.M. Glasspool, and I.A. McNeish Clear cell carcinoma of ovary and uterus Curr Oncol Rep 15 2013 566 572
29. A. Okamoto, R.M. Glasspool, S. Mabuchi, N. Matsumura, H. Nomura, H. Itamochi, and et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary Int J Gynecol Cancer 24 2014 S20 S25
30. J.E. Hutti, A.D. Pfefferle, S.C. Russell, M. Sircar, C.M. Perou, and A.S. Baldwin Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation Cancer Res 72 2012 3260 3269
31. R.L. Chandler, J.S. Damrauer, J.R. Raab, J.C. Schisler, M.D. Wilkerson, J.P. Didion, and et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling Nat Commun 6 2015 6118
32. D.R. Crotzer, C.C. Sun, R.L. Coleman, J.K. Wolf, C.F. Levenback, and D.M. Gershenson Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary Gynecol Oncol 105 2007 404 408
33. D.C. Bodurka, M.T. Deavers, C. Tian, C.C. Sun, A. Malpica, R.L. Coleman, and et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 118 2012 3087 3094
34. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, D.M. Gershenson, and et al. Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
35. J. Coward, H. Kulbe, P. Chakravarty, and et al. Interleukin-6 as a therapeutic target in human ovarian cancer Clin Cancer Res 17 2011 6083 6096
36. A.L. Rodriguez, B.M. Wojcik, S.K. Wrobleski, D.D. Myers Jr., T.W. Wakefield, and J.A. Diaz Statins, inflammation and deep vein thrombosis: a systematic review J Thromb Thrombolysis 33 2012 371 382
37. S.F. Nielsen, B.G. Nordestgaard, and S.E. Bojesen Statin use and reduced cancer-related mortality N Engl J Med 367 2012 1792 1802